

# Grŵp Strategaeth Meddyginiaethau Cymru Gyfan All Wales Medicines Strategy Group



## Final Appraisal Recommendation

Advice No: 2018 – November 2018

**Fosaprepitant (IVEMEND®) 150 mg powder for solution for infusion**

**Limited submission by Merck Sharp & Dohme Ltd**

### Recommendation of the All Wales Medicines Strategy Group

**Fosaprepitant (IVEMEND®) is recommended as an option for use within NHS Wales for the prevention of nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy in patients aged 6 months to less than 18 years of age. Fosaprepitant is given as part of a combination therapy.**

#### Additional note(s):

- Please refer to the Summary of Product Characteristics for the full licensed indication.

In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 3789), which includes the AWMSG Secretariat Assessment Report (ASAR), the Preliminary Appraisal Recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion (where available), the views of patients/patient carers (where available) and the lay member perspective.

The All Wales Therapeutics and Toxicology Centre (AWTTC) reviewed this appraisal recommendation in April 2022. No new evidence was identified that is likely to significantly affect the current recommendation. Therefore, this recommendation has been transferred to AWMSG's static list of medicine recommendations.

Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as:

All Wales Medicines Strategy Group Final Appraisal Recommendation –  
2018: Fosaprepitant (IVEMEND®) 150 mg powder for solution for infusion.  
November 2018